¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"mole fraction"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • filtration fraction
    ¿©°úºÐÀ², °Å¸£±âºÐÀ²
  • fraction
    1. ºÐ¼ö, ºÐÀ² 2. ºÎºÐ 3. ºÐȹ, ºÐÇÒ
  • fraction of inspired oxygen
    ÈíÀÔ»ê¼Ò³óµµ
  • growth fraction
    ¼ºÀåºÐÀ²
  • hypoxic fraction
    Àú»ê¼ÒºÐȹ
  • human plasma protein fraction
    »ç¶÷Ç÷Àå´Ü¹éºÐÀ²
  • inspired oxygen fraction
    µé¼û»ê¼ÒºÐÀ², Èí±â»ê¼ÒºÐÀ²
  • motor unit fraction
    ¿îµ¿´ÜÀ§ºÐȹ
  • oxygen fraction in inspired air
    ÈíÀÔ»ê¼Ò³óµµ
  • volume fraction
    ºÎÇǺÐÀ², ¿ëÀûºÐÀ²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • fraction
    ºÎºÐ, ºÐÀ², ºÐȹ
  • filtration fraction
    °Å¸£±âºÐÀ², ¿©°úºÐÀ²
  • growth fraction
    ¼ºÀåºÐÀ²
  • hypoxic fraction
    Àú»ê¼ÒºÐȹ
  • inspired oxygen fraction
    Èí±â»ê¼ÒºÐÀ²
  • motor unit fraction
    ¿îµ¿´ÜÀ§ºÐȹ
  • volume fraction
    ºÎÇǺÐÀ², ¿ëÀûºÐÀ²
  • tubular rejection fraction ratio
    ÄáÆÏ´¢¼¼°ü°ÅºÎºÐȹ·ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • reduction of fraction
    ¾àºÐ(å³ÝÂ).
  • regurgitant fraction
    ¿ª·ùºÐȹ.
  • renal fraction
    ½ÅºÐÀ².
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mole ³ª mola
    ±âÅÂ(Ðô÷Ã).
  • pigmented mole
    »ö¼Ò¸ð¹Ý(ßäáÈÙ½Úè)
  • stone mole
    ¼®È­±âÅÂ(à´ûùÐô÷Ã).
  • true mole
    Áø¼º±âÅÂ(¡­Ðô÷Ã).
  • tubal mole
    ³­°ü±âÅÂ(¡­Ðô÷Ã).
  • tubal mole
    ³­°ü±âÅÂ(¡­Ðô÷Ã)
  • vesicular mole =hydatidiform m.
    Æ÷»ó±âÅÂ(øàßÒÐô÷Ã).
  • vesicular mole =hydatidiform m.
    Æ÷»ó±âÅÂ(øàßÒÐô÷Ã)
  • absorbed fraction
    Èí¼öºÐÀ²
  • early labeled fraction
    Á¶±âÇ¥ÁöºÐȹ(¡­øöãÛÝÂüñ).
  • ejection fraction
    ¹ÚÃâ°è¼ö.
  • ejection fraction
    ¹ÚÃâÀ² (ÚÑõó×Ë)
  • ejection fraction
    ¹ÚÃâ°è¼ö(ÚÑõóÌõâ¦).
  • ejection fraction
    ±¸ÃâÀ²
  • etiologic fraction
    ¿øÀÎÀû ¿ä¼Ò
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • pre-beta fraction
    ÇÁ·¹º£Å¸ºÐȹ(ÝÂüñ)
  • saponifiable fraction
    °¡(ʦ)ºñ´©È­ ºÐȹ(ÝÂüñ)
  • saturation fraction
    Æ÷È­ ºÐȹ(øéûùÝÂüñ)
  • S-100 fraction
    S-100 ºÐȹ(ÝÂüñ)
  • soluble fraction
    °¡¿ë ºÐȹ(ʦéÁÝÂüñ)
  • subcellular fraction
    ¼¼Æ÷ÇÏ ºÐȹ(á¬øàù»ÝÂüñ)
  • volume fraction
    ¿ëÀû ºÐȹ(é»îÝÝÂüñ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
B-K initials of two patients after whom a multiple cutaneous nevus [mole] was named
FAMMM familial atypical multiple mole-melanoma [syndrome]
HM hand movements; health maintenance; heart murmur; hemifacial microsomia; Holter monitoring; home man...
IM idiopathic myelofibrosis; immunosuppressive method; implementation monitoring; Index Medicus; indome...
MIMR minimal inhibitor mole ratio
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PHM Partial hydatidiform mole
PM partial hydatidiform mole
EF Ejection Fraction
EF Etiologic Fraction
FF Filtration Fraction
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
Breus mole An aborted ovum in which the foetal surface of the placenta presents numerous haematomata with an absence of blood vessels in the chorion and an ovum much smaller in size than normal in relation to the duration of the pregnancy.
(05 Mar 2000)
carneous mole A uterine mass occurring after foetal death and consisting of blood clots, foetal membranes, and placenta.
Synonym: blood mole, carneous mole.
(05 Mar 2000)
malignant mole syndrome <syndrome> Irregularly shaped, variously coloured, distinctively melanocytic, 5 to 10 mm nevi occurring in large numbers (to over 100) primarily on the trunk and extremities, with a high risk of malignancy reported in several members and three generations of a family.
(05 Mar 2000)
vesicular mole <gynaecology, oncology, tumour> A relatively rare mass or tumour that can form within the uterus at the beginning of a pregnancy. The cause of hydatidiform mole is unknown.
Symptoms include vaginal bleeding, uterine growth, nausea and vomiting. Some hydatidiform moles may become malignant (cancerous) where they are referred to as a choriocarcinoma.
Incidence: 1 in 1,500 births.
(02 Jan 1998)
grape mole <gynaecology, oncology, tumour> A relatively rare mass or tumour that can form within the uterus at the beginning of a pregnancy. The cause of hydatidiform mole is unknown.
Symptoms include vaginal bleeding, uterine growth, nausea and vomiting. Some hydatidiform moles may become malignant (cancerous) where they are referred to as a choriocarcinoma.
Incidence: 1 in 1,500 births.
(02 Jan 1998)
mole <dermatology> A benign pigmented skin lesion or nevus.
(27 Sep 1997)
mole rats Any of several burrowing rodents of the families muridae and bathyergidae, found in eastern europe, africa, and asia. They have short limbs, small eyes with permanently closed lids, and no tail. Three genera spalax (muridae), heterocephalus (bathyergidae) and cryptomys (bathyergidae) are used frequently as experimental animals in biomedical research.
(12 Dec 1998)
water mole <zoology> The shrew mole. See Shrew.
The duck mole. See Duck.
Source: Websters Dictionary
(01 Mar 1998)
hairy mole A mole covered with an abundant growth of hair.
Synonym: hairy mole.
(05 Mar 2000)
cystic mole <gynaecology, oncology, tumour> A relatively rare mass or tumour that can form within the uterus at the beginning of a pregnancy. The cause of hydatidiform mole is unknown.
Symptoms include vaginal bleeding, uterine growth, nausea and vomiting. Some hydatidiform moles may become malignant (cancerous) where they are referred to as a choriocarcinoma.
Incidence: 1 in 1,500 births.
(02 Jan 1998)
hydatidiform mole <gynaecology, oncology, tumour> A relatively rare mass or tumour that can form within the uterus at the beginning of a pregnancy. The cause of hydatidiform mole is unknown.
Symptoms include vaginal bleeding, uterine growth, nausea and vomiting. Some hydatidiform moles may become malignant (cancerous) where they are referred to as a choriocarcinoma.
Incidence: 1 in 1,500 births.
(02 Jan 1998)
hydatidiform mole, invasive A tumour or tumour-like process invading the myometrium, and characterised by trophoblastic hyperplasia and persistence of placental villous structures. It commonly results from complete hydatidiform mole but may do so from partial hydatidiform mole. Invasive mole may metastasize but it does not exhibit the progression of a true cancer, and it may regress spontaneously. (holland et al., cancer medicine, 3d ed, p1691)
(12 Dec 1998)
hydatiform mole <radiology> Trophoblastic proliferation with avascularity of chorionic villi, marked oedema and enlargement of chorionic villi, severe eclampsia prior to 24 weeks, 1st trimester bleeding, abnormal elevation of beta-hCG, passing grapelike vesicles per vagina, uterus large for dates (50%), hyperechoic intrauterine tissue interspersed with numerous punctate hypoechoic areas (hydropic villi), in 25% atypical appearance: large hyperechoic areas (blood clots) and areas of cystic degeneration; resembles incomplete abortion, thick hyperechoic rim around central anechoic zone, bilateral theca lutein cysts (18-37%) see also: gestational trophoblastic disease, hydatiform mole: types
(12 Dec 1998)
hydatiform mole: types <radiology> Complete/classical mole, fertilization of an empty egg; diploid karyotype (paternal XX), no foetal parts; no chorionic membrane, 20% malignant complete mole with coexistent foetus (2%), molar degeneration of an identical twin partial mole, areas of molar change alternating with normal chorionic villi, triploid karyotype (66% XXY; 33% XXX), early onset of preeclampsia, foetal structures present (e.g., placenta), no malignant potential see: hydatiform mole
(12 Dec 1998)
spider mole spider angioma
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
mole fraction The number of moles of stuff in a mixture that are due to one of the compouds.
Ãâó: misterguch.brinkster.net/vocabulary.html
mole fraction Concentration of a substance in a mixture measured as moles of the substance per mole of complete mixture.
Ãâó: ibchem.com/root_htm/defn/gloss.htm
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á